Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Juergens, Heribert  [Clear All Filters]
2014
Leuchte K, Altvater B, Hoffschlag S, Potratz J, Meltzer J, Clemens D, Luecke A, Hardes J, Dirksen U, Juergens H, et al. Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function. Oncol Rep. 2014.
Ehlert K, Rossig C, Groll AH, Beyna T, Froehlich B, Juergens H. Diffuse Hemorrhagic Colitis in a Patient With Dyskeratosis Congenita After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation. J Pediatr Hematol Oncol. 2014.
2016
Thiel U, Wawer A, von Luettichau I, Bender H-U, Blaeschke F, Grunewald TGP, Steinborn M, Röper B, Bonig H, Klingebiel T, et al. Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow. Oncotarget. 2016.
2018
Whelan J, Le Deley M-C, Dirksen U, Le Teuff G, Brennan B, Gaspar N, Hawkins DS, Amler S, Bauer S, Bielack S, et al. High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol. 2018:JCO2018782516.
2019
Dirksen U, Brennan B, Le Deley M-C, Cozic N, van den Berg H, Bhadri V, Brichard B, Claude L, Craft A, Amler S, et al. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol. 2019:JCO1900915.